EP2117515A2 - Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisat - Google Patents
Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisatInfo
- Publication number
- EP2117515A2 EP2117515A2 EP08716891A EP08716891A EP2117515A2 EP 2117515 A2 EP2117515 A2 EP 2117515A2 EP 08716891 A EP08716891 A EP 08716891A EP 08716891 A EP08716891 A EP 08716891A EP 2117515 A2 EP2117515 A2 EP 2117515A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- blood plasma
- reconstitution
- styrene
- water vapor
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Definitions
- the present invention is a process for the stabilization of blood plasma ingredients of a lyophilisate and the use of a container in the method according to the invention.
- biopolymers such as proteins, polysaccharides or nucleic acids and mixtures thereof is carried out depending on the requirements of the product in a soluble, frozen (aqueous) or lyophilized state.
- all storage or dosage forms are used according to stability or mode of administration. This also applies, for example, to solutions containing individual (purified) proteins or mixtures of proteins (biopharmaceuticals), or their combination with other substances, such as lipids.
- specially optimized stabilizers are added for the respective requirements in order to keep the product in a native and active state for as long as possible.
- coagulation factors Factor II, V, VII, VIII, von Willebrand factor (VWF), VWF / FVIII complex, FIX, X, XI, XII, XIII, fibrinogen, their combinations and their activated forms
- FVII activating protease FSAP
- protease inhibitors e.g. B.
- ⁇ -1-antitrypsin antithrombin III, heparin cofactor II, Cl-esterase inhibitor, antiplasmin, protein C and its cofactor protein S, protein Z and other inhibitors, immunoglobulins such as IgG, IgA, IgE, IgM and corresponding subclasses, Proteins of fibrinolysis and the complement system such as plasminogen, plasminogen activators, complement factors, transport proteins such as albumin, transferrin, growth factors and wound healing supporting proteins such as hepatocyte growth factor, HGF, platelet-derived growth factor, PDGF, fibroblast growth factor, FGF, fibronectin , Vitronectln etc.
- plasma itself and its subfractions such as cryoprecipitate, and other familiar to the expert subfractions, such as intermediates from the plasma fractionation according to Cohn, Kistler-Nitschmann and their modifications, stored in different states.
- immunoglobulins are used in liquid or lyophilized form, the liquid variant being preferred in terms of application and convenience, since it makes the previous reconstitution unnecessary.
- liquid-stored, liquid-frozen and lyophilized variants are known and are used as required.
- a lyophilized product With intermediates from manufacturing processes of recombinant and transgenic products as well as the end products can be proceeded accordingly. Advantages of a lyophilized product are the possible comparatively longer storage at temperatures above 0 ° C., up to room temperature and beyond, combined with, as a rule, a reduced weight (due to the reduced water content). Although a lyophilized product requires reconstitution in appropriate solutions, the benefits in certain situations outweigh the benefits. Especially in emergency medicine, preferably in operations under very difficult treatment conditions, for example, outside a professional hospital area, a glass bottle is inferior by weight and possible risk of breakage a more flexible and lighter material. In addition, the cooling or thawing of the entrained frozen product (such as plasma) is time consuming.
- the lyophilization process removes water vapor from the frozen material under embodiments known to those skilled in the art.
- solutions containing, for example, carbon dioxide it may also be removed (at least partially), which may result in a shift of the pH towards basicity of the resulting product upon reconstitution with water or other solutions.
- This is observed, for example, in proteinaceous solutions, such as blood plasma.
- a pH of 7.0-7.6 before freeze-drying may reach a pH of above 8.0 upon reconstitution, as further illustrated in the example below.
- This pH shift can have consequences for product and patient. In particular, the integrity of certain active components or their stability over a longer period may be impaired.
- the more basic pH of the reconstituted product requires increased attention of the transfused patient when administered in larger volumes.
- US-A-2005/0124589 relates to the reconstitution of Iphosphamit lyophilisate with a buffer solution.
- EP-AI 417 972 relates to stabilized teriparatide solutions containing mannitol acetate or tartrate as well as M-cresol or benzyl alcohol as a preservative.
- WO-A-01/24817 discloses the reconstitution of a lyophilized composition of fibrolase or a thrombolytic, wherein the pH is maintained at pH 8.0.
- Fibrolase is an enzyme from snake serum.
- EP-A-0 284 249 relates to the lyophilization of lymphokines
- EP-B-0 124 018 relates to the preparation of a lyophilized fybronectin formulation which has been adjusted to a pH of 6.5 to 7.5 before lyophilization.
- WO-A-95/05845 relates to the preparation of a lyophilized nerve growth factor formulation wherein the composition has a pH of 5.2 after reconstitution with a solution of sodium chloride and citric acid.
- a technical problem underlying the invention was to provide an improved process which avoids or at least mitigates the disadvantages described in the handling of lyophilisates, especially in medical applications.
- the blood plasma ingredients were present in a freeze-drying process in a solution containing at least two different pH-lowering substances, which cause the setting of a predetermined pH range in the resulting in a reconstitution solution.
- the method according to the invention makes it possible for the person skilled in the art to compensate for a pH shift to be expected or arising during the reconstitution by suitable measures.
- the provision according to the invention of using at least two different substances advantageously makes it possible to provide a lyophilisate which already has the desired pH after being taken up in aqueous solutions for reconstitution. This is advantageous over the adjustment of the pH with a single substance, because then not it is ensured that the concentration of buffer substance remains below the permitted limits.
- a total of three measures are used for regulation, namely firstly the CO 2 gasification of the product to be lyophilized, for example to a pH of the solution to 6.5 to 7, then treated with a mineral acid, in particular Phosphoric acid to achieve a further reduction by, for example, 0.2 pH levels, and finally addition of another acid which is different from the first acid, for example citric acid, in order to achieve a further pH reduction, for example another 0.2 - 0.3 pH units.
- a sample prepared in this way can then be lyophilized and reaches the desired pH in the reconstituted solution, which is not detrimental to the effective protein present in the solution.
- the invention thus also provides the person skilled in the art with a technical teaching, as can be determined by simple routine experiments, with which quantity adjustments an optimum pH value can be set for the system in question.
- solution according to the invention is understood as a system in which the components are dissolved in a substantially aqueous phase, that is not a phase containing an undissolved fatty substance fraction, as described in US Pat. No. 5,690,963.
- the at least two substances prevent an adjustment of the pH in areas that the structure of the blood plasma ingredients in the lyophilisate by at least partial loss of activity and / or nativity, denaturation, fragmentation, aggregation, chemical modification how negatively affect oxidation.
- Area containing the blood plasma ingredients eg. B. Main active components of the product, not affected, it can be achieved that the pH of the product after lyophilization and reconstitution in the predetermined pH range is located.
- this predetermined range may typically be a pH range of from about 6.95 to 7.9, especially pH 7.0 to 7.6, but may require very different pH values for other biopolymer solutions.
- the pH values to be set in each case, insofar as they are already known to the person skilled in the art, can be determined in simple experiments in which, for example, B. under different pH conditions essential parameters of the ingredients, such as nativity, effectiveness, aggregation behavior, etc., are determined.
- the adjustment of the pH value is the lowering of the pH in the sense of a resulting acidic solution prior to lyophilization, by adding suitable substances, buffer solutions or (dilute) acid solutions to a desired pH after reconstitution of the product to reach.
- the adjustment of the pH range of the solution prior to lyophilization can be carried out so that a pH value which is to be present after the reconstitution in the resulting solution (predetermined pH value or pH range) is set when the reconstitution solution is used Lyophilisate is reconstituted.
- a pH value which is to be present after the reconstitution in the resulting solution predetermined pH value or pH range
- the pH of the reconstituted solution may differ significantly from the pH of the solution before freeze-drying, if tolerable.
- a solution with blood plasma ingredients having a pH of 7.4 can be adjusted to 6.0, after the reconstitution z. B. with water to reach a pH range of 6.6 to 7.0.
- Another possibility to achieve the desired pH after reconstitution of the product is the adjustment of the pH during or after dissolution of the lyophilisate. This can be done by adjusting the
- Titration of each individual vessel or withdrawn solutions takes time and is in the interest of a quick and safe application, such as e.g. one
- buffer substances such as salts of mineral or organic acids and bases are used, in particular phosphates or carbonates, whereby the pH can also be adjusted by introducing CO 2 .
- di- or Monohydrogenphosphate, bicarbonates, hydrogen sulfates, salts of organic acids or bases, tris-hydroxymethylaminomethane and / or amino acids can be used as substances for adjusting the predetermined pH.
- the reconstitution of the lyophilisate can be carried out in an aqueous solution containing physiologically acceptable acid-hydrolyzing salts or physiologically acceptable acids.
- Reconstitution may be advantageously carried out with substantially neutral water for injection when the freeze-drying of the blood plasma ingredients is in a solution containing substances which cause the setting of a predetermined pH range in the reconstitution solution.
- the procedure according to the invention is explained in more detail by way of example.
- the acidification of the product before lyophilization can be carried out with suitable solutions and substances which allow a corresponding adjustment to the pH range after dissolution of the product obtained.
- citric acid of appropriate concentration can be used to bring the pH of the plasma into the pH range of pH 6.0-6.95, preferably pH 6.5-6.95, after reconstitution of the lyophilized plasma to reach a pH of 7.0 to 7.9.
- Particularly preferred here is the addition of citric acid in the concentration range of 0.1-20.0 mM (final concentration of the added solution in the product), preferably 1-5 mM for plasma.
- Citric acid solutions for the reconstitution of lyophilized plasma also move in these concentration ranges.
- citric acid in the concentration range 0.1-50 mM (final concentration in the product of added acid) is appropriate. It should be noted that the resulting citric acid or resulting citrate content in the product may be higher overall if zltrenic acid / citrate was present before addition. This applies equally to other substances that can be added for such a setting, such as phosphate buffer, etc.
- the pH of the solution can also be effected by introducing CO 2 gas into the solution (gassing of the surface while stirring the solution or by introducing a tube into the solution or similar techniques familiar to the skilled worker) before lyophilization ,
- lyophilized vessels may also be exposed to an acidic atmosphere prior to packaging as described above. For example, by introducing CO 2 in the form of gas, diffusion into the containers takes place so that the resulting lyophilizate and later the corresponding product solution reaches the desired pH.
- the measures described for adjusting the desired pH before lyophilization, during product storage and reconstitution can be achieved by the measures described. These can be used individually or in combination. However, it is thus also possible to store the lyophilisate under acidic pH conditions, such as, for example, advantageous and known for immunoglobulins, in order then to dissolve them in water and to maintain the acidic environment and to produce a rapid
- Adjusting the pH for product solutions prior to patient application may also be necessary to achieve the required treatment effect.
- stabilizers of blood plasma ingredients in particular of therapeutically important blood plasma ingredients may be present.
- stabilizers in particular, polysaccharides, oligosaccharides, z.
- polyols such as mannitol or sorbitol, amino acids or combinations thereof.
- the lyophilizate is obtained in that the blood plasma ingredients are present in a substantially aqueous solution and filled into a container which consists at least partially of impermeable to water but permeable to water vapor and sterile material and after completion of the Freeze-drying process, a recording of water vapor above a predetermined residual moisture content of the lyophilisate is prevented.
- a container which allows shrinkage during the lyophilization process and contains microporous walls of a membrane which is permeable to water vapor but water impermeable.
- US-B-6,773,425 relates to a container for collection, freeze drying, storage, reconstitution and administration of biological solutions, in particular blood products.
- EP-A-0 343 596 relates to a method and container for freeze-drying under sterile conditions.
- the container disclosed in the document has sides with at least partially hydrophobic, porous, germ-tight and water vapor permeable membrane.
- WO-A-95/27180 relates to containers for minimizing the contamination of freeze-dried products.
- the container in question also has a location that allows water vapor to escape.
- WO-A-96/31748 relates to a bag for holding solutions to be freeze-dried and also having a water vapor permeable sterile barrier disposed on a backing material.
- the rapid recovery of water vapor in the plastic vessel can be prevented or made more difficult by several measures in the process of the invention.
- the reduction of the relative humidity in the removal area and / or the flooding of the lyophilizer with nitrogen or other suitable measures are practicable.
- the rapid covering or sealing of the membrane surface by suitable measures such as application of water vapor-impermeable and sterile films or the rapid closing of the vessels in suitable foil pouches make the absorption of moisture difficult or even prevent. This can be done under nitrogen or bag evacuation.
- the material known to those skilled in the art for binding water (vapor) can be added to the bag, depending on which residual moisture range is to be set.
- Lyophilisate which can be reconstituted according to the invention may be present.
- the method according to the invention is not limited to these blood plasma proteins.
- Therapeutically significant as blood plasma Ingredients in particular proteins from blood, plasma or serum, as well as recombinant or transgenic blood plasma proteins.
- proteins isolated from blood plasma such as coagulation factors (Factor II, V, VII, VIII, von Willebrand Factor (VWF), VWF / FVIII complex, FIX, X, XI, XII, XIII, fibrinogen, their combinations and their activated forms), FVII-activating protease (FSAP), protease inhibitors, e.g. B.
- ⁇ -1-antitrypsin antithrombin III, heparin cofactor II, Cl-esterase inhibitor, antiplasmin, protein C and its cofactor protein S, protein Z and other inhibitors, immunoglobulins such as IgG, IgA, IgE, IgM and corresponding subclasses, Proteins of fibrinolysis and the complement system such as plasminogen, plasminogen activators complement factors, transport proteins such as albumin, transferrin, growth factors and wound healing supporting proteins such as hepatocyte growth factor, HGF, platelet-derived growth factor, PDGF, fibroblast growth factor, FGF, fibronectin, Vitronectin, etc., and their combinations, as well as plasma (in the form of, for example, citrate plasmas, oxalate or heparin plasma) itself and its subfractions, such as cryoprecipitate, and other subfractions familiar to the skilled worker, such as intermediates from plasma fractionation after Cohn, Kistler-Nitschmann and their modifications.
- blood plasma ingredients which are contained in biological sources such as body fluids from transgenic or fractions with recombinantly produced proteins come into consideration.
- the method according to the invention is carried out in containers in which the water vapor-permeable sterile material consists of fluorinated plastic materials, polyester or polyethylene.
- plastic materials in the form of suitable containers can also be used as support material for the containers in which the lyophilization takes place.
- suitable containers such as sachets
- These may consist of materials such as polypropylene, polyethylene, ethylvinylacetate, polyvinylchloride, polyurethane or other suitable materials or their combinations and layers, such as Kraton® polymers, which may consist of multilayer systems known to those skilled in the art and combinations thereof with other materials.
- the Kraton® polymers are block polymers of styrene / butadiene / styrene, styrene / isoprene / styrene, styrene / ethylene-butylene / styrene, styrene / ethylene-propylene / styrene, each of which can also carry functional groups, such as maleic anhydride.
- membranes may consist of polytetrafluoroethylene (fluoropolymers) polypropylene, polyethylene or other suitable membranes and combinations thereof. Not every membrane material is simply compatible with the bag material in the sense of a tight connection to be made eg welding. Corresponding combinations are combined with one another by techniques familiar to the person skilled in the art, for example by thermal welding and / or mechanical anchoring or other suitable methods.
- Preferred combinations are vascular matter of polypropylene and / or Kraton polymers with fluoropolymer-based materials membranes, preferably polytetrafluoroethylene or polypropylene, and preferably vessels made of polyethylene with polyethylene-based membranes, such as the so-called high density polyethylenes.
- Multilayer systems also provide a base for vessels to ensure stability, sterility, and water and gas tightness, which can be connected to suitable membrane materials.
- the membranes may form the entire bag, but it will generally be preferred to obtain only a portion of the bag in the form of such a membrane.
- lyophilization usually takes place in such a way that the plastic container in the lyophilizer rests on a (cooled, to be cooled) solid surface and thus part of the membrane surface is not available for maximum water vapor emission. Furthermore, re-entry of water vapor into the lyophilizate after opening the lyophilizer will generally be significantly accelerated over a plastic vessel with an optimized membrane fraction.
- a particular embodiment of such a vessel represents a bag made of polypropylene, the surface of which on one side consists of a large proportion (> 50% of this unilateral surface facing the lyophilizer space) of the membrane, which is freely accessible during lyophilization, ie facing away from the cooling surface on which the vessel is placed.
- the membrane fraction of this accessible surface should be as large as possible so that the freeze-drying process can be carried out effectively. If, for example, the membrane surface is too small relative to the bag surface (if, for example, the membrane edge is too far from the edge of the bag and the solution underneath), then the vapor molecules must first move horizontally through the solution / lyophilisate during evaporation in order then to exit through the membrane can. This can, in addition to a prolonged lyophilization lead to undesirable inhomogeneities of the lyophilisate (areas with incomplete drying, inclusions).
- a water vapor impermeable container which may consist of plastics or aluminum foil.
- Lyophilization be performed.
- this can also be done in a method in which a freeze-drying process is used which comprises a first and a second step, wherein in the second step of the freeze-drying process, a lower desorption energy input into the freeze-drying process than in the first step.
- This method is the subject of European patent application EP-AI 870 649 and described in more detail there. On the EP-AI 870 649 is hereby incorporated by reference.
- the inventive method can be carried out in particular using a container as shown schematically in the figure.
- the container for lyophilization has walls 10 and connecting elements 21, 22.
- the walls 10 are at least partially made of impermeable to water but permeable to water vapor and sterile material 15.
- the connection element 22 may be formed as a connection nozzle and be closed by a septum 23.
- the filling of the bag can be done for example by the filling hose 21.
- the wall 10 is interrupted here in the visible part through the window 15.
- the window 15 is made of a water vapor permeable but water impermeable material. This material is described in detail above.
- the aim of this experiment was to investigate in principle the kinetics of the re-absorption of water vapor by the lyophilized product and the influence of ambient temperature and humidity.
- glass bottles (20 ml) with narrow neck / inlet were filled with 5 ml plasma (1 cm filling height) and lyophilized.
- the control batches were sealed airtight whereas other bottles were either at room temperature / 60%.
- the analysis of the residual moisture contents of the lyophilizates was carried out according to the Karl Fischer method known to the person skilled in the art.
- the results show that the residual moisture increase of the lyophilisate is relatively fast and depends on the ambient temperature and humidity. Accordingly, measures can be taken to limit an undesirably high residual moisture content.
- the control samples (0 hours, ie directly after lyophilizer removal) show that the Residual moisture can be kept in a desired range by a suitable method (rapid airtight seal).
- the findings obtained above were taken into account by the lyophilisate-containing vessels after removal from the lyophilizer were sealed airtight in a plastic bag in a timely manner.
- polypropylene containers were used in the form of a bag as outlined in the figure, wherein the polytetrafluoroethylene membrane was applied on one side surface (after previous preparation of a corresponding window on a bag side), thus resulting in a liquid-tight connection.
- Inlet and outlet elements for filling the bag, possibly rapid venting in the sense of displacement of the air in the bag by the incoming liquid are present.
- inlet and outlet elements also allow the entry of a reconstitution liquid after freeze-drying and outlet for the reconstituted solution to be taken, in the practical application for infusion to the patient.
- These inlet / outlet connections may consist of plastic materials known in the art, in the example described polypropylene.
- the inlet compound was sealed, the bags were frozen and subjected to freeze-drying. After drying, the bags were removed from the lyophilizer and immediately sealed in plastic bags and sealed airtight.
- the lyophilisate-containing vessels were removed from the protective pouches (after prior opening by slicing) and then admixed with 184 ml of fluid as described below to give a final volume of 200 ml of reconstituted plasma. Under Slight panning of the bags was followed by complete reconstitution to a clear solution within 5 minutes.
- Example 1 Vessels that had been stored sealed in bags for days and several weeks. In contrast, lyophilisates which had not been sealed for weeks in corresponding bags, residual moisture contents of significantly more than 3%, as could be assumed in principle from the result of Example 1.
- Example 2 The procedure was as in Example 2, including use of the plastic materials, freeze-drying conditions and handling.
- the vessels in the form of membrane-containing bags were filled with 200 ml of plasma.
- a coagulating solvent / detergent-treated human blood plasma and the universally usable blood plasma according to WO-A-2005/058334 and EP-AO 991 416 was used. Both anticoagulant products are produced after defrosting and combining up to 1,520 individual plasma donations using a strictly controlled manufacturing process under GMP conditions.
- the Solvent / Detergent process implemented in the production process achieves a very high level of security in terms of minimizing an infectious residual risk (for transfusion-relevant enveloped viruses). Individual donor screening and other safety measures and effective process steps also contribute significantly to the safety of the products at.
- Universally useful plasma is achieved by the optimal integration of individual donations of blood groups A, B and AB in described mixing ratios (as in EP-A-0 991 416 and EP-A-1 696 940 described), which allows the blood group-independent application to the patient.
- Citric acid was added to the S / D-treated plasma pool (human blood plasma and universal plasma method) by dropwise addition, with thorough mixing by stirring, to a final concentration of 'added citric acid' of 3-4 mM, the pH being Value was lowered from pH 7.0-7.4 to pH 6.5-6.7. After sterile filtration, the resulting plasma was filled into the vessels for subsequent freeze-drying. The reconstitution of the lyophilizates was carried out by adding in each case 184 ml of water for injections (WFI).
- WFI water for injections
- Human blood plasma / universal plasma was prepared and filled without the addition of pH-lowering solutions.
- the reconstitution of the lyophilizates was carried out by adding 184 ml each of WFI containing citric acid in a concentration of 3-4 mM.
- Human blood plasma / universal plasma was prepared and filled without addition of pH lowering solutions. The reconstitution of the lyophilizates was carried out by adding in each case 184 ml of WFI, but without the addition of citric acid, D. Human blood plasma / universal plasma was filled into commercially available bags and stored frozen. The non-lyophilized product was used as a control.
- coagulation factors Factors II, V, VII, VIII, IX, X, XI, XII, XIII, ADAMTS13
- inhibitors antithrombin III, proteins C and S, alpha-1-antitrypsin, antiplasmin and Cl inhibitor
- so-called global coagulation parameters were determined, which may indicate an impairment of one or more factors: activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT) and reptilase time (RT).
- aPTT activated partial thromboplastin time
- PT prothrombin time
- TT thrombin time
- RT reptilase time
- markers such as the thrombin-antithrombin complex (TAT), prothrombin fragments (Fl + 2), activated factor VII (FVIIa) and D-dimers.
- Batch B pH 7.3 to 7.6
- Batch C pH 8.1 to 8.4
- the reconstituted C approaches showed reduced activity on Factor VIII and Protein S as compared to the control, as well as a prolonged reptilase time.
- the pH can be adjusted before lyophilization to reach the desired pH range (A) or by reconstitution with an appropriate solution (B).
- the pH was adjusted to 6.9 in the plasma pool by CO 2 gassing.
- phosphoric acid was added to the plasma pool by dropping, with good mixing by stirring, to a final concentration of the added phosphoric acid of 2 mM, the pH being lowered further to 6.7.
- C. The plasma pool in batch B was additionally treated with citric acid
- the plasma pool from batch B was additionally citric acid by dropwise, with thorough mixing by stirring, to a
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Fertilizers (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08716891A EP2117515A2 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisat |
EP11193532A EP2431024A1 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur Stabilisierung von Blutplasma Inhaltsstoffen in einem Lyophilisat |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07102446A EP1958618A1 (de) | 2007-02-15 | 2007-02-15 | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
PCT/EP2008/051888 WO2008099016A2 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisat |
EP08716891A EP2117515A2 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisat |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2117515A2 true EP2117515A2 (de) | 2009-11-18 |
Family
ID=38069354
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07102446A Withdrawn EP1958618A1 (de) | 2007-02-15 | 2007-02-15 | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
EP08716891A Withdrawn EP2117515A2 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisat |
EP11193532A Withdrawn EP2431024A1 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur Stabilisierung von Blutplasma Inhaltsstoffen in einem Lyophilisat |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07102446A Withdrawn EP1958618A1 (de) | 2007-02-15 | 2007-02-15 | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11193532A Withdrawn EP2431024A1 (de) | 2007-02-15 | 2008-02-15 | Verfahren zur Stabilisierung von Blutplasma Inhaltsstoffen in einem Lyophilisat |
Country Status (4)
Country | Link |
---|---|
US (1) | US8518452B2 (de) |
EP (3) | EP1958618A1 (de) |
CN (1) | CN101610756A (de) |
WO (1) | WO2008099016A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140083628A1 (en) | 2012-09-27 | 2014-03-27 | Velico Medical, Inc. | Spray drier assembly for automated spray drying |
GB201122430D0 (en) * | 2011-12-23 | 2012-02-08 | Xstalbio Ltd | Reconstitution method for high concentration dry protein formulation |
US9561893B2 (en) | 2013-12-05 | 2017-02-07 | Vascular Solutions, Inc. | System and method for freeze-drying and packaging |
EP3151662B1 (de) | 2014-06-09 | 2020-10-21 | Terumo BCT, Inc. | Lyophilisierung |
WO2016034719A2 (en) * | 2014-09-04 | 2016-03-10 | Petr Dejmek | A process and a container for dehydration of a product |
US9561184B2 (en) | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
US10806665B2 (en) | 2016-01-18 | 2020-10-20 | Teleflex Life Sciences Limited | System and method for freeze-drying and packaging |
GB2564481B (en) | 2017-07-14 | 2019-10-23 | 4D Pharma Leon S L U | Process |
JP7110360B2 (ja) * | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ,エルエルシー | 凍結乾燥方法 |
US20200208110A1 (en) | 2018-11-30 | 2020-07-02 | Cellphire, Inc. | PLATELETS LOADED WITH mRNA |
US10945959B2 (en) | 2019-03-07 | 2021-03-16 | Teleflex Life Sciences Limited | System and method for freeze-drying and packaging |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
AU2020267368B2 (en) | 2019-05-03 | 2023-05-04 | Cellphire, Inc. | Materials and methods for producing blood products |
US20210069240A1 (en) * | 2019-09-05 | 2021-03-11 | Cellphire, Inc. | Materials and methods for blood plasma preparations |
WO2021158645A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Methods of treating congenital hemophilia with anti-fibrinolytic loaded platelets |
CN114617903B (zh) * | 2022-03-15 | 2024-05-24 | 中国人民解放军总医院第一医学中心 | 一种用于血浆冻干的组合物及其应用 |
US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
US11998861B2 (en) | 2022-09-15 | 2024-06-04 | Velico Medical, Inc. | Usability of a disposable for a spray drying plasma system |
US11975274B2 (en) | 2022-09-15 | 2024-05-07 | Velico Medical, Inc. | Blood plasma product |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0124018B1 (de) * | 1983-04-28 | 1987-11-25 | Armour Pharmaceutical Company | Pharmazeutische Zubereitung mit Gehalt an gereinigtem Fibrinonectin |
EP0284249A1 (de) * | 1987-03-13 | 1988-09-28 | Interferon Sciences, Inc. | Gefriergetrocknete Lymphokin-Zusammensetzung |
DE3817906A1 (de) * | 1988-05-26 | 1989-11-30 | Boehringer Mannheim Gmbh | Verfahren und behaeltnis zum gefriertrocknen unter sterilen bedingungen |
US5309649A (en) * | 1988-05-26 | 1994-05-10 | Boehringer Mannheim Gmbh | Process and container for freeze drying under sterile conditions |
US6277828B1 (en) * | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
AU7356094A (en) * | 1994-04-04 | 1995-10-23 | W.L. Gore & Associates, Inc. | Improved method for minimizing contamination of freeze-dried products |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
AU4755196A (en) * | 1995-04-07 | 1996-10-23 | W.L. Gore & Associates, Inc. | A freeze-drying bag and method for minimizing contamination of freeze-dried products |
US5690963A (en) * | 1995-06-30 | 1997-11-25 | The United States Of America As Represented By The Secretary Of The Navy | Freeze dried red blood cells |
EP0896824A1 (de) | 1997-08-05 | 1999-02-17 | Octapharma Ag | Universell verwendbares Bluttplasma |
ZA9811127B (en) * | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
US6517526B1 (en) * | 2000-12-29 | 2003-02-11 | Yehuda Tamari | Container for lyophilizing biological products |
CA2452395C (en) | 2001-07-10 | 2012-04-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Pharmaceutically stable hemostatic compositions |
US7422726B2 (en) * | 2002-10-23 | 2008-09-09 | Blood Cell Storage, Inc. | Integrated container for lyophilization, rehydration and processing of biological materials |
WO2005032515A1 (en) * | 2003-10-01 | 2005-04-14 | Baxter International Inc. | New use, pharmaceutical preparations as well as a process for their production |
AU2004298790B2 (en) | 2003-12-19 | 2010-04-08 | Octapharma Ag | A universally applicable virus inactivated blood plasma produced from portions of non-caucasian plasma |
EP1870649A1 (de) | 2006-06-20 | 2007-12-26 | Octapharma AG | Gefriertocknung zum Erzielen einer bestimmte Restfeuchte durch beschränkte Desorptionsenergiepegeln. |
-
2007
- 2007-02-15 EP EP07102446A patent/EP1958618A1/de not_active Withdrawn
-
2008
- 2008-02-15 EP EP08716891A patent/EP2117515A2/de not_active Withdrawn
- 2008-02-15 EP EP11193532A patent/EP2431024A1/de not_active Withdrawn
- 2008-02-15 WO PCT/EP2008/051888 patent/WO2008099016A2/de active Application Filing
- 2008-02-15 CN CNA2008800051190A patent/CN101610756A/zh active Pending
- 2008-02-15 US US12/449,558 patent/US8518452B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
BAKALTCHEVA IRINA ET AL: "Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, vol. 120, no. 1, 1 January 2007 (2007-01-01), pages 105 - 116, XP002437509, ISSN: 0049-3848, DOI: 10.1016/J.THROMRES.2006.07.005 * |
Also Published As
Publication number | Publication date |
---|---|
CN101610756A (zh) | 2009-12-23 |
US20100159023A1 (en) | 2010-06-24 |
WO2008099016A3 (de) | 2008-11-27 |
EP1958618A1 (de) | 2008-08-20 |
EP2431024A1 (de) | 2012-03-21 |
US8518452B2 (en) | 2013-08-27 |
WO2008099016A2 (de) | 2008-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008099016A2 (de) | Verfahren zur stabilisierung von blutplasma inhaltsstoffen in einem lyophilisat | |
RU2700162C2 (ru) | Расширенная под вакуумом сухая композиция и шприц для ее сохранения | |
RU2142290C1 (ru) | Водный раствор фактора viii со сниженной концентрацией кислорода | |
DE69433939T2 (de) | Hämostatisches pflaster | |
EP1574222B1 (de) | Sterilisationsprozess für Steroide | |
RU2678592C1 (ru) | Сухая композиция, содержащая компонент, улучшающий экструзию | |
DE19903876A1 (de) | Verfahren zur Induktion von prophylaktisch oder therapeutisch wirksamen Proteinen | |
EP1124589B1 (de) | Fibrin-gewebekleber-formulierung und verfahren zu dessen herstellung | |
EP0796623A2 (de) | Pharmazeutisches Präparat zur Behandlung von Blutgerinnungs-störungen | |
EP1183043B1 (de) | Arzneimittel zur lokalen anwendung, das fibrinogen, thrombin, transglutaminasen und proteinaseinhibitoren enthält | |
WO1994013329A1 (de) | Verfahren zur herstellung eines virussicheren biologischen präparates | |
EP0973544B1 (de) | Immuntolerante prothrombinkomplex-präparation | |
WO2009155626A2 (de) | Lagerstabiles, funktionell intaktes fibrinogen | |
EP0343596A2 (de) | Behälter zum Gefriertrocknen unter sterilen Bedingungen | |
AT411326B (de) | Hämostatische collagen-pellets | |
EP0625908B1 (de) | Antidot für hirudin und synthetische thrombininhibitoren | |
WO2016169630A1 (de) | Verfahren zur sterilisierung eines chromatographiematerials und danach sterilisiertes chromatographiematerial | |
EP1528930B1 (de) | Thrombingenerierfähige und thrombinhaltige pharmazeutische wirkstoffzubereitungen und arzneimittel | |
EP3092009B1 (de) | Lyophilisierte mesna-zusammensetzungen | |
EP1344521A1 (de) | Verfahren zur Rekonstitution von lyophilisierten Proteinen | |
EP1216028B1 (de) | Bioabbaubare trägersysteme für therapeutisch wirksame substanzen und verfahren zu deren herstellung | |
WO1999002169A1 (de) | Verfahren zur herstellung von virusinaktiviertem blutplasma oder blutserum in lyophilisierter form | |
JP7147017B2 (ja) | テリパラチド又はその塩を含有する無菌注射剤を製造する方法 | |
AT402892B (de) | Verfahren zur herstellung eines virussicheren biologischen präparates | |
EP2727584A1 (de) | Abgase zur Verwendung beim Trocknen, Lagern bzw. Rekonstituieren von Biomolekülen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090626 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BJOERNSTRUP, KIM Inventor name: GRUBER, GERHARD Inventor name: HEGER, ANDREA Inventor name: SCHUETZ, RAIMUND Inventor name: SACHSE, HANS Inventor name: SVAE, TOR-EINAR Inventor name: ROEMISCH, JUERGEN Inventor name: KERN, MARTIN |
|
17Q | First examination report despatched |
Effective date: 20091204 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160630 |